このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Passage Bio マネジメント
マネジメント 基準チェック /14
現在、CEO に関する十分な情報がありません。
主要情報
Will Chou
最高経営責任者
US$1.4m
報酬総額
| CEO給与比率 | 41.4% |
| CEO在任期間 | 1.7yrs |
| CEOの所有権 | n/a |
| 経営陣の平均在職期間 | 1.3yrs |
| 取締役会の平均在任期間 | 3.3yrs |
経営陣の近況
Recent updates
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Jun 11
We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Feb 27Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully
Jun 23Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13Passage appoints William Chou CEO
Oct 10Passage Bio GAAP EPS of -$0.73 beats by $0.09
Aug 04We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Jun 03Passage Bio: Worth Keeping An Eye On
Apr 11Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?
Dec 15Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans
Aug 19Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing
Jun 06Passage Bio partners with InformedDNA to offer counseling, testing for early dementia
May 03We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely
Mar 08Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?
Feb 01
Passage Bio on go with PBGM01 gene therapy trial in the U.S.
Jan 04Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares
Dec 28U.K. authorizes Passage Bio's PBGM01 trial
Dec 10Passage Bio (PASG) Investor Presentation - Slideshow
Nov 16Passage Bio EPS beats by $0.13
Nov 10Passage Bio’s PBKR03 nabs Orphan drug tag and accelerated review status for Krabbe disease
Oct 28CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$84m |
| Dec 31 2023 | US$1m | US$599k | -US$102m |
| Sep 30 2023 | n/a | n/a | -US$112m |
| Jun 30 2023 | n/a | n/a | -US$112m |
| Mar 31 2023 | n/a | n/a | -US$128m |
| Dec 31 2022 | US$1m | US$112k | -US$136m |
報酬と市場: Willの 総報酬 ($USD 1.45M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。
報酬と収益: Willの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Will Chou (51 yo)
1.7yrs
在職期間
US$1,448,546
報酬
Dr. William Chou, MD, also known as Will, has been the Chief Executive Officer and Director of Passage Bio, Inc. from October 10, 2022 and serves as its President. Dr. Chou is an accomplished executive wit...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 1.7yrs | US$1.45m | データなし | |
| General Counsel & Company Secretary | 4.8yrs | US$804.69k | 0.080% $ 39.3k | |
| Chief Medical Officer | 2.9yrs | US$1.01m | 0.079% $ 38.6k | |
| Co-Founder & Chief Scientific Advisor | no data | データなし | データなし | |
| Senior VP | less than a year | データなし | 0.046% $ 22.6k | |
| Senior Vice President of Corporate Development & Investor Relations | 3.3yrs | データなし | データなし | |
| Senior Vice President of Technical Operations | less than a year | データなし | データなし | |
| Senior Vice President of Research & Development | less than a year | データなし | データなし | |
| Senior Vice President of Global Regulatory Affairs | less than a year | データなし | データなし |
1.3yrs
平均在職期間
60yo
平均年齢
経験豊富な経営陣: PASGの経営陣は 経験豊富 とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 1.7yrs | US$1.45m | データなし | |
| Independent Chairwoman of the Board | 3.3yrs | US$101.34k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$65.84k | 0.0081% $ 4.0k | |
| Independent Director | 4.3yrs | US$69.97k | 0.031% $ 15.0k | |
| Independent Director | 4.5yrs | US$73.34k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$69.30k | 0% $ 0 | |
| Independent Director | less than a year | US$49.90k | 0% $ 0 |
3.3yrs
平均在職期間
53yo
平均年齢
経験豊富なボード: PASGの 取締役会 は 経験豊富 であると考えられます ( 3.3年の平均在任期間)。